(Q48668455)

14 February 2018

title

What is the best long-term management strategy for patients with primary adrenal insufficiency? (English)

1 reference

14 February 2018

author

Stefanie Hahner

series ordinal

2

1 reference

14 February 2018

Marcus Quinkler

series ordinal

1

object named as

Marcus Quinkler

1 reference

14 February 2018

1 January 2012

1 reference

14 February 2018

published in

Clinical Endocrinology

1 reference

14 February 2018

volume

76

1 reference

14 February 2018

issue

1

1 reference

14 February 2018

page(s)

21-25

1 reference

14 February 2018

cites work

Adrenal insufficiency

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Addison's disease in women is a risk factor for an adverse pregnancy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Plasma catecholamines in patients with Addison's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

High-calorie glucose-rich food attenuates neuroglycopenic symptoms in patients with Addison's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Adrenal crisis in treated Addison's disease: a predictable but under-managed event

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Therapeutic management of adrenal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Why is the management of glucocorticoid deficiency still controversial: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Long-term follow-up of bone mineral density in Addison's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

Predisposing factors for adrenal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

The effect of o,p'-DDD on adrenal steroid replacement therapy requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04103.X

10.1111/J.1365-2265.2011.04103.X

21 January 2018

Identifiers

DOI

1 reference

14 February 2018

PubMed ID

21585418

1 reference

14 February 2018